Geron(US:GERN)2025-05-07 11:05Financial Performance - Geron Corporation reported $39.4 million in net product revenue from RYTELO® (imetelstat) in Q1 2025, with demand relatively flat compared to previous periods[1][4][7]. - Total net revenue for Q1 2025 was $39.6 million, a significant increase from $0.3 million in the same period in 2024[1][8]. - Geron reported a net loss of $19.8 million, or $0.03 per share, for Q1 2025, an improvement from a net loss of $55.4 million, or $0.09 per share, in Q1 2024[1][6]. - Basic and diluted net loss per share for Q1 2025 was $0.03, compared to $0.09 in Q1 2024[38]. Operating Expenses - Total operating expenses for Q1 2025 were $56.3 million, slightly down from $56.4 million in the same period in 2024[1][9]. - Research and development expenses decreased to $15.1 million in Q1 2025 from $29.4 million in Q1 2024, primarily due to reduced clinical trial costs[1][10]. - Selling, general and administrative expenses increased to $40.0 million in Q1 2025 from $27.1 million in Q1 2024, reflecting higher personnel costs for commercialization efforts[1][11]. - Geron maintains its 2025 financial guidance for total operating expenses in the range of $270 million to $285 million[1][14]. - The company projects total operating expenses for fiscal year 2025 to be managed effectively to reach profitability without additional financing[35]. Cash and Assets - As of March 31, 2025, Geron had approximately $457.5 million in cash and marketable securities, down from $502.9 million at the end of 2024[1][5]. - Current assets increased to $495.769 million as of March 31, 2025, from $490.992 million at the end of 2024[40]. - Cash, cash equivalents, and restricted cash rose to $85.610 million from $80.876 million at the end of 2024[40]. - Current liabilities decreased to $63.034 million from $88.298 million at the end of 2024[40]. Clinical Trials and Product Launch - Approximately 85% enrollment has been reached in the Phase 3 IMpactMF clinical trial, with an interim analysis expected in the second half of 2026[1][4]. - The company received marketing authorization for RYTELO from the European Commission, planning to launch in select EU countries in 2026[1][4]. - The company expects to commercialize RYTELO in select EU countries in 2026[35]. - The company anticipates that U.S. sales of RYTELO will be sufficient to fund projected operating requirements for the foreseeable future[35].